1-20 of 1959
protein tyrosine kinase
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Poor prognosis is ZAP70’ed into focus in CLL

Adam J. Linley, Joseph R. Slupsky
Journal: Blood
Blood (2021) 137 (26): 3586–3587.
https://doi.org/10.1182/blood.2021011270
Published: 2021
Journal Articles

Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia

Eun Ji Gang, Hye Na Kim, Yao-Te Hsieh, Yongsheng Ruan, Heather A. Ogana, Solomon Lee, Jennifer Pham, Huimin Geng, Eugene Park, Lars Klemm, Cheryl L. Willman, William L. Carroll, Steven D. Mittelman, Etan Orgel, Matthew J. Oberley, Chintan Parekh, Hisham Abdel-Azim, Deepa Bhojwani, Alan S. Wayne, Adèle De Arcangelis, Elisabeth Georges-Labouesse, Elizabeth Wayner, Halvard Bonig, Aspram Minasyan, Johanna ten Hoeve, Thomas G. Graeber, Markus Müschen, Nora Heisterkamp, Yong-Mi Kim
Journal: Blood
Blood (2020) 136 (2): 210–223.
https://doi.org/10.1182/blood.2019001417
Published: 2020
Includes: Supplemental data
Journal Articles

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia

Jun Long, Ming-Yuan Jia, Wei-Yue Fang, Xin-Jie Chen, Li-Li Mu, Zhong-Yu Wang, Yan Shen, Ru-Fang Xiang, Li-Ning Wang, Ling Wang, Chuan-He Jiang, Jie-Ling Jiang, Wen-Jun Zhang, Yi-Dan Sun, Li Chang, Wen-Hui Gao, Ying Wang, Jun-Min Li, Deng-Li Hong, Ai-Bin Liang, Jiong Hu
Journal: Blood
Blood (2020) 135 (17): 1472–1483.
https://doi.org/10.1182/blood.2019003538
Published: 2020
Includes: Supplemental data
Journal Articles

FER and FES tyrosine kinase fusions in follicular T-cell lymphoma

Koen Debackere, Jo-Anne van der Krogt, Thomas Tousseyn, Julio Antonio Finalet Ferreiro, Katrien Van Roosbroeck, Lukas Marcelis, Carlos Graux, Daan Dierickx, Geneviève Ameye, Peter Vandenberghe, Lucienne Michaux, Jan Cools, Iwona Wlodarska
Journal: Blood
Blood (2020) 135 (8): 584–588.
https://doi.org/10.1182/blood.2019002401
Published: 2020
Includes: Supplemental data
Journal Articles

Targeted Protein Degradation of BTK As a Unique Therapeutic Approach for B Cell Malignancies

Aileen Kelly, PhD, Daniel W Robbins, May Tan, Austin Tenn-McClellan, Joel McIntosh, Jeffrey Wu, Zef Konst, Daisuke Kato, Luz Perez, Jennifer Tung, Anna Kolobova, Timothy Ingallinera, Jenny McKinnell, Dahlia Weiss, Mark Noviski, Jordan Ye, Ge Peng, Mario Cardozo, Jeff Mihalic, Steve Basham, Ryan Rountree, Dane E Karr, Neil Bence, Christoph W Zapf, Arthur T Sands
Journal: Blood
Blood (2019) 134 (Supplement_1): 3805.
https://doi.org/10.1182/blood-2019-129262
Published: 2019
Journal Articles

Efficacy of Targeted Therapy in Novel Pre-Clinical in Vitro and In Vivo Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)

Vrajesh Karkhanis, PhD, Warren Fiskus, BSc,PhD, Christopher Peter Mill, PhD BA, Abhishek Maiti, MBBS, Bernardo H Lara, James V Maher, Isean Bhalla, Nancy Shao, Michael R Green, PhD, Joseph D. Khoury, MD, Kapil N. Bhalla, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3961.
https://doi.org/10.1182/blood-2019-132041
Published: 2019
Journal Articles

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Katelyn M. Melgar, PhD, LaQuita M Jones, DO, Mackenzie Walker, Lyndsey C Bolanos, BSc, Kathleen Hueneman, Mark Wunderlich, MS, Jiang-Kang Jiang, Kelli Wilson, Xiaohu Zhang, Patrick Sutter, Xin Xu, Kwangmin Choi, PhD, Gregory Tawa, Donald Lorimer, Jan Abendroth, Eric O'Brien, BSc, Scott Hoyt, Ellin Berman, MD, Christopher Famulare, MS, James C Mulloy, Ross L. Levine, MD, Jan S Rosenbaum, John P Perentesis, Craig J Thomas, PhD, Daniel T. Starczynowski, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3934.
https://doi.org/10.1182/blood-2019-124178
Published: 2019
Journal Articles

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

Dirk Reinhardt, MD, Christian Michel Zwaan, Albert Hoenekopp, Julie Niolat, Sophie Ifrah, Florence Noel-Baron, Franco Locatelli, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3835.
https://doi.org/10.1182/blood-2019-128043
Published: 2019
Journal Articles

Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies

Chan Y. Cheah, Nicholas Wickham, MBBS, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Katharine L Lewis, FRCPath, MRCP, MBBS, Chi-Hung Hui, MBBS, Pek Sang Tang, MBBS, Tejasvi Turpuseema, Hari P Miskin, MSc, Jian-Ping Tang, PhD, Emmanuel Normant, PhD, Alejandro D. Ricart, MD, Constantine S. Tam, MBBS (Hons), MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4001.
https://doi.org/10.1182/blood-2019-126951
Published: 2019
Journal Articles

Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma

Shelby Sloan, BS, Fiona Brown, BS, JI Hyun Chung, PhD, Alexander Prouty, BS, Esther Wheeler, BS, Bonnie K Harrington, DVM, PhD, Eric Brooks, BS, Ayse S Yilmaz, MS, Hatice G Ozer, PhD, John C. Byrd, MD, Selina Chen-Kiang, PhD, Maurizio Di Liberto, PhD, Rosa Lapalombella, PhD, Kris Vaddi, PhD, Peggy Scherle, PhD, Youssef Youssef, MD, Robert A Baiocchi, MD PhD, Lapo Alinari, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4065.
https://doi.org/10.1182/blood-2019-128998
Published: 2019
Journal Articles

The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3 -Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

David Cella, PhD, Ellen K. Ritchie, MD, Francesco Fabbiano, Arnaud Pigneux, Yoshinobu Kanda, MD PhD, Cristina Ivanescu, PhD, Bhavik J. Pandya, PharmD, Manasee V Shah, MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 3850.
https://doi.org/10.1182/blood-2019-123790
Published: 2019
Journal Articles

Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinases Exerts Synergistic Effect Against Chronic Myeloid Leukemia Cells

Sylwia Flis, Ewelina Bratek, Tomasz Chojnacki, Marlena Piskorek, Tomasz Skorski, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4143.
https://doi.org/10.1182/blood-2019-129093
Published: 2019
Journal Articles

A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Max S. Topp, MD, Johannes Duell, MD, Jingjin Li, PhD, Vladimir Jankovic, MD, Israel Lowy, MD PhD, David Sternberg, MD PhD, Lieve Adriaens, PharmD, Mary Peterman, PharmD, Srikanth R. Ambati, MBBS, MD, Rajat Bannerji, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4007.
https://doi.org/10.1182/blood-2019-126670
Published: 2019
Journal Articles

A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma

Jason R. Westin, MD, Nathan H. Fowler, MD, Loretta J. Nastoupil, MD MSc, Sattva S Neelapu, MD, Hun Ju Lee, Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Raphael E Steiner, MD, Sairah Ahmed, MD, Simrit Parmar, MBBS, Ranjit Nair, MBBS,MD, Rebecca Harrison, MD, Luis Fayad, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4086.
https://doi.org/10.1182/blood-2019-131463
Published: 2019
Journal Articles

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma

Mehrdad Mobasher, MD MPH, Richard A. Miller, MD, James W. Janc, PhD, Long Kwei, PhD, Joseph J. Buggy, PhD, Gabriel Luciano, Anahita Mohammady, PharmD, Won Seog Kim, MD PhD, Youn H. Kim, MD, Michael S. Khodadoust, MD PhD, Steven M. Horwitz, MD, Dejan Radeski, MBBS, FRACP, FRCPA
Journal: Blood
Blood (2019) 134 (Supplement_1): 4030.
https://doi.org/10.1182/blood-2019-124958
Published: 2019
Journal Articles

Discovery of DWP213388, a Potent ITK and BTK Selective Dual Inhibitor with Excellent Efficacy and Safety, for Treating Gvhd

Deokki Eom, BS, Jae Hun Jung, Eun Kyung KIM, PhD, Wolyoung Kim, Qingri Li, Jaehyun Jung, Sohee Im, Yong Dae Shin, Hyaejung Hyun, Joon Seok Park
Journal: Blood
Blood (2019) 134 (Supplement_1): 4426.
https://doi.org/10.1182/blood-2019-126839
Published: 2019
Journal Articles

The Risk of Bleeding in Patients Receiving Ibrutinib Combined with Novel Direct Oral Anticoagulants

Michal Ariela Raz, MD, Jon E. Arnason, MD, Osnat Bairey, MD PhD, Lev Shvidel, MD, Ariel Aviv, MD, Sharon Ben Baruch, MD, Chava Perry, MD PhD, Nadav Sarid, MD, David Varon, MD, Ilya Kirgner, MD, Yair Herishanu, MD, Irit Avivi
Journal: Blood
Blood (2019) 134 (Supplement_1): 4314.
https://doi.org/10.1182/blood-2019-125356
Published: 2019
Journal Articles

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Afsar Ali Mian, BSc, MPhil, PhD, Usva Zafar, BSc, Oliver Ottmann, Prof, MD, Martin Ruthardt, MD, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA
Journal: Blood
Blood (2019) 134 (Supplement_1): 2570.
https://doi.org/10.1182/blood-2019-130898
Published: 2019
Journal Articles

A Novel BCL-2/BCL-Xl Dual Inhibitor Overcomes Ibrutinib-Resistance Conferred By the Upregulation of Integrin Pathway and BCL-Xl

Jing Deng, PhD, Tingting Mao, MS, Xiaojing Huang, PhD, Li Rui, Guangfeng Wang, PhD, Douglas D. Fang, MD PhD, Dajun Yang, MD PhD, Yifan Zhai, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2573.
https://doi.org/10.1182/blood-2019-128708
Published: 2019
Journal Articles

Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia

Janani Ravikrishnan, Tzung-Huei Lai, PhD DVM, Elizabeth Muhowski, Lindsey Brinton, PhD, Katie Williams, MS, Alexandria Thompson, James S. Blachly, MD, Hatice Gulcin Ozer, PhD, John C. Byrd, MD, Rosa Lapalombella, PhD, Jennifer Woyach, MD, Deepa Sampath, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2526.
https://doi.org/10.1182/blood-2019-128574
Published: 2019